Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
643
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Andreas Pintera Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, GermanyView further author information
,
Kilian Eyerichb Department of Dermatology and Venerology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany;c Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenView further author information
,
Antonio Costanzod Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy;e Dermatology, Humanitas Research Hospital IRCCS, Rozzano, Milan, ItalyView further author information
,
Alyssa Garreltsf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Christopher Schusterf Eli Lilly and Company, Indianapolis, Indiana, USA;g Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information
,
Can Merth HaaPACS GmbH, Schriesheim, GermanyView further author information
,
Anastasia Lampropoulouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Konstantinos Fotiouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Julia-Tatjana Mauli Department of Dermatology, University Hospital Zurich, Zurich, Switzerland;j Faculty of Medicine, University of Zürich, Zurich, SwitzerlandView further author information
&
Kim A. Pappk Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada;l Division of Dermatology, Department of Medicine, University of Toronto, Ontario, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9557-3642View further author information
ORCID Icon show all
Article: 2350227 | Received 29 Feb 2024, Accepted 24 Apr 2024, Published online: 26 May 2024

Figures & data

Figure 1. Actual response rates and adjusted odds ratios of PASI 100, for IXE vs. other drugs, anti-IL-17A vs other drug classes, and anti-IL-17A vs other biologics at week 12 among patients with psoriasis stratified by ≤2 years and >2 years disease duration. Disease duration of ≤2 years is depicted by top/square lines, and >2 years disease duration is depicted by bottom/circle lines. Results are statistically significant if 1 is not covered by the 95% CI. Unadjusted CIs were calculated using the normal approximation.

CI: confidence interval; IL: interleukin; IXE: ixekizumab; NRI: nonresponder imputation; PASI: Psoriasis Area and Severity Index; TNF: tumor necrosis factor. *denotes that lower CI is greater than 1.

Figure 1. Actual response rates and adjusted odds ratios of PASI 100, for IXE vs. other drugs, anti-IL-17A vs other drug classes, and anti-IL-17A vs other biologics at week 12 among patients with psoriasis stratified by ≤2 years and >2 years disease duration. Disease duration of ≤2 years is depicted by top/square lines, and >2 years disease duration is depicted by bottom/circle lines. Results are statistically significant if 1 is not covered by the 95% CI. Unadjusted CIs were calculated using the normal approximation.CI: confidence interval; IL: interleukin; IXE: ixekizumab; NRI: nonresponder imputation; PASI: Psoriasis Area and Severity Index; TNF: tumor necrosis factor. *denotes that lower CI is greater than 1.
Supplemental material

Supplemental Material

Download MS Word (133.2 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.